Jason Harris - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jason Harris's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jason Harris
Verified
Senior Editor, OncLive
Beats
Healthcare Medicare Pharmaceuticals
never say never
Content
By Jason Harris Verified| ONCOLOGY journal Verified Disease recurrence, minimal residual disease (MRD) status, and clinical benefit with adjuvant atezolizumab (Tecentriq) among those with renal cell carcinoma (RCC) may correlate with the presence of circulating kidney injury molecule-1 (KIM-1), according to retrospective data from the phase 3 IMmotion010 trial (NCT03024996) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Previously reported topline results from the IMmotion010 trial showed that atezolizumab...
By Jason Harris Verified| CURE Magazine Verified Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell therapy targeting the “enigmatic” GPRC5D antigen which generated remissions in 70.6% of patients, according to data from a first-in-human phase 1 trial. Twelve of 17 patients experienced a measurable decline in their cancer after receiving MCARH109 CAR-T cells. Six patients (35%) achieved complete response and 10 patients (59%) had very good partial response or better.
By Jason Harris Verified| ONCOLOGY journal Verified Disease recurrence, minimal residual disease (MRD) status, and clinical benefit with adjuvant atezolizumab (Tecentriq) among those with renal cell carcinoma (RCC) may correlate with the presence of circulating kidney injury molecule-1 (KIM-1), according to retrospective data from the phase 3 IMmotion010 trial (NCT03024996) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Previously reported topline results from the IMmotion010 trial showed that atezolizumab...
Company Info
OncLive
NeurologyLive is a multimedia platform focused on delivering the latest news and insights in the field of neurology. It serves as a valuable resource for healthcare professionals, particularly those treating neurological diseases. The platform offers a combination of print and digital media, ensuring that busy clinicians stay informed about significant developments in neurology. The services provided by NeurologyLive include breaking news on drug approvals, clinical trials, and emerging trends in neurological care. It features expert interviews with leading neurologists, offering insights into the latest research and clinical practices. The use of multimedia content makes the information accessible and engaging for its audience. NeurologyLive targets healthcare professionals such as neurologists, clinicians, and researchers. It has established strategic partnerships with organizations like the Consortium of Multiple Sclerosis Centers, enhancing its credibility and reach within the neurology community. Its comprehensive coverage and expert engagement position NeurologyLive as a trusted source for the latest developments in the field.
Cranbury, United States
+1 609-716-7777
Founded: 2018